U.S. markets open in 2 hours 55 minutes

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
455.35+9.94 (+2.23%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Outside Bar (Bearish)

Outside Bar (Bearish)

Previous Close445.41
Open443.79
Bid442.26 x 900
Ask467.64 x 1100
Day's Range442.23 - 457.57
52 Week Range260.42 - 555.77
Volume531,457
Avg. Volume965,409
Market Cap66.481B
Beta (5Y Monthly)0.94
PE Ratio (TTM)106.39
EPS (TTM)4.28
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est410.18
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
23% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hedge Funds Are Buying Illumina, Inc. (ILMN)
    Insider Monkey

    Hedge Funds Are Buying Illumina, Inc. (ILMN)

    Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

  • Reuters

    EU antitrust regulators set July 27 deadline for Illumina, Grail deal

    EU antitrust regulators will rule by July 27 whether to clear Illumina Inc's proposed $7.1 billion acquisition of cancer test maker Grail Inc , a European Commission filing showed on Thursday. U.S. life sciences company Illumina, which is also challenging the EU watchdog's decision to review the deal even though it does not meet the EU revenue criteria, filed for EU approval on Wednesday. The company has said it will pursue a dual-track tactic, launching litigation against the Commission while following the EU merger process.

  • Has Illumina Lost Its Shine?
    Motley Fool

    Has Illumina Lost Its Shine?

    In 2016, Cathie Wood and ARK investment management described Illumina (NASDAQ: ILMN) as "the cornerstone of our Genomic Revolution theme, and one of our highest conviction stocks." Illumina became one of the largest holdings across several ARK ETFs including the ARK Innovation ETF (NYSEMKT: ARKK) and ARK Genomic Revolution ETF (NYSEMKT: ARKG). What was behind ARK's loss of conviction in Illumina?